Manjunatha, Ujjini Havaldar, Diagana, Thierry Tidiane, Leong, Franz Joel Wen and Chao, Alexander (2016) Cryptosporidiosis drug discovery: Opportunities and Challenges. ACS Infectious Diseases, 2 (8). pp. 530-537. ISSN 10.1021

Abstract

Apicomplexan parasite Cryptosporidium is the second most important diarrheal pathogen causing a life-threatening diarrhea in children and is also associated with long-term growth faltering and cognitive deficiency. Currently, nitazoxanide is the only approved treatment for cryptosporidum infections. Unfortunately it has limited efficacy in most vulnerable patients, thus there is an urgent need for a safe and efficacious cryptosporidiosis drug. The main objective of our cryptosporidiosis program is to identify new chemotypes active against both Cryptosporidium parvum and C. hominis. In this article, we share our current thinking on the ‘target product profile’ for cryptosporidiosis and our perspective on perceived risks and possible mitigation plans at different stages of cryptosporidiosis drug discovery. Through a global collaborative effort and increased investments in drug discovery and development, a safe and efficacious cryptosporidiosis drug is possible.

Item Type:	Article
Date Deposited:	16 Sep 2016 00:45
Last Modified:	16 Sep 2016 00:45
URI:	https://oak.novartis.com/id/eprint/29637